NCT06506955

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

RecruitingPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2024-10-01Est. Completion: 2027-04

Enrollment target: 15 participants

Locations

University of California, San Francisco (UCSF), San Francisco, California, United States
Institut Paoli-Calmettes, Marseille, France
Institut De Cancerologie Strasbourg, Strasbourg, France
Severance Hospital, Seoul, South Korea
Hospital Universitari, Vall d'Hebron, Barcelona, Spain
Centro Integral Oncologico, Madrid, Spain
Royal Marsden NHS Foundation Trust, London, United Kingdom
Sarah Cannon Research Institute UK, London, United Kingdom
University College London Hospitals NHS Foundation Trust, London, United Kingdom

Other microbiome trials you might be interested in

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid TumorsPhase 1Recruiting

Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Non-small Cell Lung Cancer (NSCLC)HR+/HER2- Ductal Breast Cancer (BC)HR+/HER2- Lobular Breast Cancer (BC)Triple Negative Breast Cancer (TNBC)Colorectal Cancer (CRC)Soft Tissue Sarcoma (STS)

The purpose of Part 1 of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokine…

Chuo Ku, JapanEst. completion Jan 16, 2028

View Trial →

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic TreatmentCompleted

Liver Metastasis Colon Cancer

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.